×
Hero Background

Chromoblastomycosis Treatment Companies

ID: MRFR/Pharma/4230-HCR
120 Pages
Rahul Gotadki
October 2025

Chromoblastomycosis is a chronic fungal skin infection that requires specialized medical treatment. Antifungal medications and, in some cases, surgical intervention may be part of the treatment plan.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Chromoblastomycosis Treatment Market Research Report -Forecast to 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Chromoblastomycosis Treatment Market

Chromoblastomycosis Treatment Market


Latest Chromoblastomycosis Treatment Companies Updates


Novartis launches antifungal Posaconazole (Noxafil®) injection in India: This expands accessibility of a potent antifungal medication for chromoblastomycosis treatment in a region with high disease burden.


Eisai announces positive Phase 2b trial results for its investigational antifungal agent E1201 for the treatment of chromoblastomycosis: These promising results offer hope for a new treatment option with potentially improved efficacy and tolerability.


AmplyMed receives FDA Fast Track designation for its investigational antifungal Fumagilin for the treatment of chromoblastomycosis: This designation expedites development and regulatory review, potentially bringing a new treatment option to market faster.


List of Chromoblastomycosis Treatment Key companies in the market:



  • Astellas Pharma (Japan)

  • Biocon Limited (India)  

  • Abbott Laboratories (U.S.)

  • Merck Sharp and Dohme (U.S.)

  • Gilead Sciences (U.S.)

  • Mylan Labs (U.S.)

  • Bristol Myers Squibb (U.S.)

  • Bayer AG (Germany)

  • Lonza Group (Switzerland)

  • Sanofi (France)